Skip to main content
. 2017 Jun 6;2017(6):CD012143. doi: 10.1002/14651858.CD012143.pub2
Methods For characteristics see ADVANCE 2011a2
Participants
Interventions
Outcomes
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding of participants and personnel (performance bias) All outcomes Unclear risk Described as being double‐blinded but it was unclear how the blinding was performed
Blinding of outcome assessment (detection bias) All outcomes Unclear risk Described as being double‐blinded but it was unclear how the blinding was performed
Incomplete outcome data (attrition bias) All outcomes Low risk < 5% dropped out
Selective reporting (reporting bias) Low risk All outcomes stated in the protocol were assessed
Vested‐interest bias High risk The trial was funded by Bristol‐Myers Squibb
Other bias Low risk The trial appeared to be free of other components that could put it at risk of bias